Search hospitals > California > Concord

John Muir Medical Center-Concord Campus

Claim this profile
Concord, California 94520
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Ovarian Cancer
Conducts research for Breast Cancer
Conducts research for Fallopian Tube Cancer
140 reported clinical trials
4 medical researchers
Photo of John Muir Medical Center-Concord Campus in ConcordPhoto of John Muir Medical Center-Concord Campus in ConcordPhoto of John Muir Medical Center-Concord Campus in Concord

Summary

John Muir Medical Center-Concord Campus is a medical facility located in Concord, California. This center is recognized for care of Cancer, Recurrence, Ovarian Cancer, Breast Cancer, Fallopian Tube Cancer and other specialties. John Muir Medical Center-Concord Campus is involved with conducting 140 clinical trials across 194 conditions. There are 4 research doctors associated with this hospital, such as Babak Edraki, MD, Gigi Q. Chen, Tiffany H. Svahn, and Wilson Tsai, MD.

Area of expertise

1Cancer
Global Leader
John Muir Medical Center-Concord Campus has run 37 trials for Cancer. Some of their research focus areas include:
Stage II
HER2 positive
Stage III
2Recurrence
Global Leader
John Muir Medical Center-Concord Campus has run 19 trials for Recurrence. Some of their research focus areas include:
Stage III
Stage IV
BRCA1 positive

Top PIs

Clinical Trials running at John Muir Medical Center-Concord Campus

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Heart Failure
Cancer
Colorectal Cancer
Squamous Cell Carcinoma
ALK Gene Rearrangement
Syndrome
Ovarian Cancer
Image of trial facility.

Chemotherapy Reduction After Surgery

for Breast Cancer

This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at John Muir Medical Center-Concord Campus?
John Muir Medical Center-Concord Campus is a medical facility located in Concord, California. This center is recognized for care of Cancer, Recurrence, Ovarian Cancer, Breast Cancer, Fallopian Tube Cancer and other specialties. John Muir Medical Center-Concord Campus is involved with conducting 140 clinical trials across 194 conditions. There are 4 research doctors associated with this hospital, such as Babak Edraki, MD, Gigi Q. Chen, Tiffany H. Svahn, and Wilson Tsai, MD.